WO2005074943A1 - Ed−71製剤 - Google Patents
Ed−71製剤 Download PDFInfo
- Publication number
- WO2005074943A1 WO2005074943A1 PCT/JP2005/001749 JP2005001749W WO2005074943A1 WO 2005074943 A1 WO2005074943 A1 WO 2005074943A1 JP 2005001749 W JP2005001749 W JP 2005001749W WO 2005074943 A1 WO2005074943 A1 WO 2005074943A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydroxypropoxy
- triol
- triene
- solution
- secocholesta
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
- A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Definitions
- the present invention relates to (5Z, 7E)-(1R, 2R, 3R) —2— (3-hydroxypropoxy) -9,10—secocholesta 5, 7, 10 (19) —triene 1,3 It relates to a preparation containing 25-triol (hereinafter also referred to as “ED-71”).
- vitamin D derivatives preparation methods such as soft capsules can be used.
- the known vitamin D derivatives preparations for example, 1 a, by ⁇ Ka ⁇ the tocopherols such 0.5 01 5 wt 0/0 to pharmaceutical compositions containing 25-dihydroxy cholecalciferol Schiff Errol, la, It has been reported that 25-dihydroxycholecalciferol can be kept stable (Japanese Patent Laid-Open No. 87750/1994), and a soft capsule containing alpha-calcidol containing dl- ⁇ -tocopherol and dibutylhydroxytoluene at a weight ratio of 1: 1.
- An object of the present invention is to provide a pharmaceutical formulation capable of suppressing the generation of a decomposition product of ED-71.
- the antioxidant is preferably dl-a-tocopherol, dibutylhydroxytoluene, butylhydroxysol, or propyl gallate.
- a Tokopherol is even more preferred! /.
- the above-mentioned preparation is preferably a soft capsule, a hard capsule or an oily liquid (particularly a soft capsule), which is preferably an oily preparation.
- (5E, 7E) — (1R, 2R, 3R) —2— (3-hydroxypropoxy) -9, which is a trans-isomer of ED-71 , 10—Secokolesta—5, 7, 10 (1 9) —Triene 1, 3, 3, 25—Triol is provided.
- ED-71 preparation of the present invention it is possible to provide a pharmaceutical formulation capable of suppressing the generation of a decomposition product of ED-71.
- the trans form can be used as a standard product in the formulation analysis of ED-71, and also as a raw material for synthesizing various vitamin D-based compounds.
- FIG. 1 The UV-HPLC chromatograph (265 nm) of the drug solution after leaving it at 40 ° C. and 75% RH for 33 days is inadequate.
- ED-71 can be prepared, for example, according to the method described in JP-A No. 10-72432, (1R, 2R, 3R) -2- (3-hydroxypropoxy) cholesta-5,7-gen 1,3,25 —Using triol as a starting material, it can be obtained by purifying by reverse-phase HPLC after ultraviolet irradiation and thermal isomerization reaction, concentrating, and crystallizing with ethyl acetate.
- the "antioxidant" used in the present invention includes nitrite (eg, sodium nitrite), sulfite (eg, sodium sulfite, dried sodium sulfite, sodium hydrogen sulfite, sodium pyrosulfite), thiosulfate ( For example, sodium thiosulfate), alpha thioglycerin, 1,3-butylene glycol, thioglycolic acid and its salts (eg, sodium thioglycolate), thiomalate (eg, sodium thiomalate), thiourea, thiolactic acid, Tolates (eg, sodium edetate), dichlorisyanurate (eg, potassium dichlorinate), citric acid, cysteine and its salts (eg, cysteine hydrochloride), benzotriazole, 2-mercaptobenzimidazole, erythorbic acid and Its salts (for example, sodium erythorbic acid) Thor
- dl ⁇ -tocopherol, dibutylhydroxytoluene, butylhydroxysol, propyl gallate is more preferred, and dl-a tocopherol is particularly preferred! /.
- the "oils and fats" used in the present invention include medium-chain fatty acid triglyceride (hereinafter, also referred to as "MCT"), tricaprylin, caproic acid, force prillic acid, force pric acid, oleic acid, linoleic acid, and linolenic. Acids, vegetable oils and the like.
- examples of the vegetable oil include coconut oil, olive oil, rapeseed oil, falling raw oil, corn oil, soybean oil, cottonseed oil, grape oil, safflower oil and the like.
- MCT which does not contain unsaturated fatty acids and which is preferred by MCT, tricaprylin, caproic acid, caprylic acid, and capric acid is particularly preferred.
- the "decomposed product of ED-71” refers to a main decomposed product detected when ED-71 is stored as an oily preparation, and specifically, a taxosterol derivative of ED-71 and It is a transformer of ED-71.
- the taxosterol derivative of ED-71 is a compound having a taxosterol skeleton and represented by the following structural formula, and its chemical name is 6E- (1R, 2R, 3R) -2- (3-hydroxypropoxy). -9, 10—Secokolesta 5 (10), 6, 8 (9) —Trien 1, 3, 25—triol). [0029] [Formula 4]
- the taxosterol compound can be synthesized, for example, according to the method described in JP-A-10-72432, or can also be synthesized by the following method. That is, (1R, 2R, 3R) -2- (3-hydroxypropoxy) -cholesta-5,7-gen 1,3,25-triol was used as a starting material, and its tetrahydrofuran solution was exposed to ultraviolet light at low temperature under argon atmosphere. After irradiation, the product is purified by reverse-phase HPLC and concentrated to dryness to give a taxosterol compound.
- the trans form of ED-71 is a compound represented by the following structural formula in which the double bond at the 5-6 position is in the trans configuration, and its chemical name is (5E, 7E)-(1R, 2R , 3R) —2— (3-hydroxypropoxy) —9,10—secocholesta—5,7,10 (19) Triene 1,3,25—triol.
- the presence of the taxosterol form and the trans form can be confirmed by detecting them by reversed-phase liquid chromatography and measuring the absorbance at a measurement wavelength of 265 nm.
- the state in which the generation of the decomposition product of ED-71 is suppressed is preferably such that the amount of each of the taxosterol form and the trans form when stored at room temperature and protected from light for 12 months is 1% or less, respectively. Is more preferably 0.3% or less, particularly preferably 0.1% or less.
- an "oil preparation” refers to a solution prepared by dissolving a drug in fats and oils into a dosage form capable of oral administration.
- examples of the oily preparation that can be used include soft capsules, hard capsules, and oily liquids.
- the soft capsule is a capsule in which a compounded solution in which a drug is dissolved in fats and oils is enclosed in a film mainly composed of a film-forming component such as gelatin.
- a shift may be used as long as a method capable of producing a soft capsule such as a dropping method or a rotary die method can be used.
- the rotary-die method is a method in which a continuous sheet (a sheet containing a gel-forming component such as gelatin) passes through two opposing rotating forming rollers, and the capsule former is pushed out of the sheet by the rollers and filled simultaneously. The material is injected between the two blanks, and the ends of the blanks are welded together by heat to form a seam soft capsule.
- Vitamin D soft capsules and methods for producing them include, for example, those described in International Publication WO 01/15702 ⁇ -, International Publication WO 02Z13755, International Publication WO 03Z09 4897, International Patent Application PCTZJP03Z07885, and the like. Can be mentioned.
- Hard capsules are defined as a capsule containing a film-forming component such as gelatin as a main component and a shell capsule having a body force filled with a solution containing a drug, and polymerized between the cap and the body so that the solution does not leak.
- the part is coated with a gelatin solution or the like and sealed.
- the films of the soft capsule and the hard capsule are composed of a film-forming component, a plasticizer, a light-shielding agent, and the like, and are blended with them.
- the film-forming component may be an animal-derived component such as various gelatins or a non-animal-derived component such as various water-soluble polymers. Can be used.
- Animal-derived components include alkali-treated gelatin, acid-treated gelatin, chemically modified gelatin, and the like.
- the chemically modified gelatin the modification mode is not particularly limited, and those produced by reacting a substance such as succinic acid, phthalic acid, or acetic acid with an amino group of gelatin can be used.
- Gelatin used for chemically modified gelatin may be alkali-treated gelatin or acid-treated gelatin.
- Non-animal-derived components include seaweed such as agar, carrageenan, and alginic acid.Polysaccharides extracted, roast bean gum, guar gum, tamarind gum, cassia gum, tara bean gum and other plant seeds. Polysaccharides, such as gum arabic, tragacanth, almond gum, damson gum, etc. And polysaccharides obtained from microorganisms such as curdlan, and fibrous mucilage such as crystalline cellulose, methylcellulose, carboxymethylcellulose, and hydroxypropylmethylcellulose.
- plasticizer examples include glycerin, sorbitol, maltose, glucose, maltose, sucrose, xylitol, mannitol, erythritol, polyethylene glycols (molecular weight: 400-6000), and the like. In the present invention, these plasticizers are used. One or more can be used.
- metal oxides such as titanium oxide, iron sesquioxide (iron oxide), yellow iron sesquioxide, yellow iron oxide and zinc oxide, talc, calcium carbonate, magnesium carbonate, magnesium silicate, and light anhydrous Inorganic compounds such as citric acid, caramel, food red No.3 aluminum lake, food yellow No.4 aluminum lake, food yellow No.5 aluminum lake, food green No.3 aluminum lake, food blue No.2 aluminum lake, copper blue no.2 aluminum lake, sodium copper chlorophyllin, etc.
- these water-insoluble light-shielding agents can be used.
- the "oil solution” is a solution in which a drug-containing oil solution is filled in a sealed container (eg, a glass container, a plastic container, a stick packaging container, or the like).
- a sealed container eg, a glass container, a plastic container, a stick packaging container, or the like.
- the amount of fats and oils used in the present formulation is not particularly limited, but for capsules (soft capsules and hard capsules), the amount is preferably 50 to 500 mg, more preferably 60 to 250 mg per capsule.
- the amount of the oil or fat used in the case of the oily liquid is preferably 0.5 to 5 g per container, more preferably 11 to 3 g.
- the ED-71 content in the preparation is not particularly limited, it is contained in an amount of 0.05-5 g as the amount of ED-71 per unit preparation! It is particularly preferred that 0.75 / zg is included!
- 0.00001% by weight or more is preferred 0.00002% by weight or more is particularly preferred 0.01% by weight or less is preferred 0 0.00125% by weight or less is particularly preferred.
- 0.0 for oily liquids 0.0001% by weight or more is preferred. 0.000017% by weight or more is particularly preferred. 0.001% by weight or less is preferred. 0.000075% by weight or less is particularly preferred.
- the amount of the antioxidant in the fat or oil is not particularly limited, but is not more than the maximum amount that can be used as an antioxidant (for example, as described in the Pharmaceutical Excipients Dictionary (Yakuji Nippo, 2000)). In general, a food additive official standard (the amount less than the use limit amount described in the Japanese Food Additives Association, 1999) or less can be used.
- dl ⁇ -tocopherol in the case of capsules, it is preferable that 0.001% by weight or more is contained in fats and oils, more preferably 0.002% by weight or more. It is particularly preferable that the content be 01% by weight or more, preferably 12% by weight or less, more preferably 1% by weight or less, and particularly preferably 0.1% by weight or less. .
- an oily liquid it is preferably contained in oils and fats in an amount of at least 0.0001% by weight, more preferably at least 0.002% by weight, particularly preferably at least 0.01% by weight.
- the content is preferably 1.2% by weight or less, more preferably 1% by weight or less, and particularly preferably 0.1% by weight or less. The same applies to dibutylhydroxytoluene, butylhydroxysol, propyl gallate, and the like, as in the case of dl ⁇ -tocopherol.
- ED-71 and the taxosterol compound used were those synthesized by the method described in JP-A-10-72432.
- Example 1 Trans form ((5 ⁇ .7E)-(1R. 2R. 3R) —2- (3-hydroxypropoxy)
- the obtained white solid was dissolved using a small amount of ethanol and 0.5 mL of ethyl acetate, and crystallized in a freezer set at 20 ° C. The precipitated crystals were separated, washed with a small amount of ethyl acetate, and dried to obtain 39 mg of the trans form (22% yield).
- HPLC purity 99.6% (HPLC conditions: Kromasil ODS 100-5C18, 5 m, 4.6 mml. D.X 250 mm, 55% aqueous solution of acetonitrile, flow rate 0.9 mLZ min, 220 lmg / mL 10 ⁇ L, area measurement range Half an hour) .
- UV (ethanol) ( ⁇ max): 209.8 nm ( ⁇ 12300), 274.6 nm ( ⁇ 23200).
- IR (KBr) (cm ⁇ 1 ): 3365, 2951, 2935, 2877, 2845, 1628, 1468, 1458, 14 37, 1375, 1363, 1350, 1333, 1215, 1120, 1080, 1059, 1034, 997, 958, 947, 933, 904, 891, 872, 729, 715, 683, 638, 627.
- Example 2 Identification of main degradation product in soft capsule containing ED-71
- Tritium-labeled ED—71 (2 j8 — ([3 ”H] —3-hydroxypropyl) —1 ⁇ , 3 ⁇ —25 Trihydroxycholesta 5, 7, 10 (19) —triene (or (5 ⁇ , 7E) - (1R, 2R , 3R) - 2- ([3- 3 H] - 3- hydroxypropoxy) -9, 10 Sekokoresuta 5, 7, 10 (19) Toryen - 1, 3, 25-triol both title to. hereinafter referred to as "3 H- ED- 71") with (J. Labele d Cpd. Radiopharm.
- FIGS. 1 and 2 Chromatograms obtained by HPLC of the drug solution after standing at 40 ° C and 75% RH for 33 days are shown in FIGS. 1 and 2, respectively.
- RI chromatogram in addition to the main peak corresponding to ED-71 and the minor peak corresponding to the pre form at around 17 minutes, minor peaks were also detected around 16 minutes and around 24 minutes, respectively.
- These two species peaks Do is detected in front of the sample stored at 40 ° C / 7 5% RH !, It, and RI- detected peak by HPLC has a peak derived from 3 H- ED- 71 Therefore, the power of these two components 3 ⁇ 4D— 71 It was suggested that this was the main decomposition product of.
- the pre-form of ED-71 is a compound that exists as an isomer in equilibrium with ED-71 in an oil solution, an aqueous solution, or an organic solvent such as ethanol (Japanese Patent Laid-Open No. No. 10-72432), which is represented by the following structural formula.
- Table 1 shows the formulation of the test soft capsule.
- ED-71 was blended at 0.0001% by weight with respect to MCT.
- antioxidants dl- ⁇ -tocopherol (manufactured by Wako Pure Chemical Industries) and ⁇ (dibutylhydroxytoluene) (manufactured by Wako Pure Chemical Industries) alone or in combination Using.
- the amount of each antioxidant added was 0.02% by weight based on the MCT.
- Formulations containing antioxidants were designated as prescriptions 1, 2, and 3, and those containing no antioxidant were designated control formulation 1.
- Soft capsules were manufactured using a seamless capsule filling machine (Spherex, manufactured by Freund Corporation) by the dropping method so that the weight of the drug solution and the weight of the film per capsule were 100 mg and 65 mg, respectively.
- Spherex manufactured by Freund Corporation
- each soft capsule solution was withdrawn and 50 L of it was subjected to HPLC analysis.
- the ratio of the peak area of the taxosterol form or trans form to the sum of the detected peak areas was calculated and used as an index of the amount of production.
- the ED-71 content was measured by the following HPLC method, and the residual ratio after the end of the storage period was determined.
- MCT ⁇ solution was used as a standard solution.
- the capsule solution was also withdrawn from the solution, and about 300 mg of the solution was precisely weighed into a 10 mL pear-shaped flask. After accurately adding 2 mL of the internal standard solution, evaporate it at room temperature.
- Tables 2-4 show the results of detection of the taxosterol form, trans form, and ED-71 by HPLC.
- n l, N.D. ⁇ 0.1%
- Control formula 1 Formula 1 Formula 2 Process 3 Storage conditions Storage period (months) Unattached calo l IT Tocopherol BHT + Tocohue ⁇ — ⁇ ⁇
- Table 5 shows the formulation of the test soft capsule.
- ED-71 was blended at 0.001% by weight with respect to MCT.
- the formulation containing no dl- ⁇ -tocopherol was designated as Control Formulation 2.
- Soft capsules were manufactured using a seamless capsule filling machine (Spherex, manufactured by Freund Corporation) by the dropping method so that the chemical solution weight and the film weight per capsule were 100 mg and 65 mg, respectively.
- Spherex manufactured by Freund Corporation
- Tables 6 and 7 show the results of detection of the taxosterol form and the trans form by HPLC.
- A-Tocopherol is added in Kazuko
- d- ⁇ -tocopherol inhibited the production of ED-71 main degradation products in a concentration-dependent manner, and even at 0.002% by weight of dl- ⁇ -tocopherol-added kamul, significant main degradation products were formed. It was shown to have an inhibitory effect.
- ED-71 was blended at 0.0017% by weight with respect to MCT.
- antioxidants dl-a tocopherol (manufactured by Wako Pure Chemical Industries), dibutylhydroxytoluene (manufactured by Wako Pure Chemical Industries), butylhydroxydisole (manufactured by Wako Pure Chemical Industries), propyl gallate (Wako Pure Chemical Industries) Industrial) were used alone.
- Each antioxidant was added in an amount of 0.2% by weight based on MCT.
- Formulations containing antioxidants were designated as prescriptions 9, 10, 11, and 12;
- Table 8 shows the results of detection of the taxosterol form and the trans form by HPLC.
- Control formulation 3 Not used 0.76 0.43 Treatment 9 dl — Tocohue mouth N.D.N.D.Formulation 10 Dibutyl hydroxytonolene N.D.
- An ED-71-containing preparation was prepared according to the method described in Example 4 except that the test capsule was a soft capsule having the following formulation, and the formation behavior of a taxosterol form and a trans form was evaluated. V. Even with the prescription of deviation, the production of taxosterol form and trans form was suppressed. [Table 9] j1 ⁇ 2 9 Soft force
- ED-71 preparation of the present invention it is possible to provide a formulation capable of suppressing the generation of a decomposition product of ED-71.
- the trans form is useful as a standard product in the formulation analysis of ED-71, and is also useful as a raw material for synthesizing various vitamin D-based compounds.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020067017923A KR101166394B1 (ko) | 2004-02-06 | 2005-02-07 | Ed-71 제제 |
JP2005517763A JP4921794B2 (ja) | 2004-02-06 | 2005-02-07 | Ed−71製剤 |
ES05709801.4T ES2638836T3 (es) | 2004-02-06 | 2005-02-07 | Preparación de ED-71 |
CN2005800098776A CN1938034B (zh) | 2004-02-06 | 2005-02-07 | Ed-71制剂 |
EP05709801.4A EP1714656B8 (en) | 2004-02-06 | 2005-02-07 | Ed-71 preparation |
US10/588,609 US20070129340A1 (en) | 2004-02-06 | 2005-02-07 | Ed-71 preparation |
HK07109267.0A HK1101139A1 (en) | 2004-02-06 | 2007-08-27 | Ed-71 preparation |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004030702 | 2004-02-06 | ||
JP2004-030702 | 2004-02-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005074943A1 true WO2005074943A1 (ja) | 2005-08-18 |
Family
ID=34836013
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2005/001749 WO2005074943A1 (ja) | 2004-02-06 | 2005-02-07 | Ed−71製剤 |
Country Status (8)
Country | Link |
---|---|
US (1) | US20070129340A1 (ja) |
EP (1) | EP1714656B8 (ja) |
JP (2) | JP4921794B2 (ja) |
KR (1) | KR101166394B1 (ja) |
CN (2) | CN101721708B (ja) |
ES (1) | ES2638836T3 (ja) |
HK (2) | HK1101139A1 (ja) |
WO (1) | WO2005074943A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009524578A (ja) * | 2006-01-24 | 2009-07-02 | 株式会社アールテック・ウエノ | 二環式化合物を含む医薬組成物およびその二環式化合物の安定化方法 |
WO2018124260A1 (ja) * | 2016-12-28 | 2018-07-05 | 中外製薬株式会社 | Ed-71の固体分散体および油分分散体を含む医薬組成物 |
JP2018528985A (ja) * | 2015-09-18 | 2018-10-04 | プラティ、ドナドゥッチ エー シア リミターダ | カンナビノイドを含む経口医薬組成物、その調製及び使用のための方法 |
JP2019014676A (ja) * | 2017-07-06 | 2019-01-31 | 東海カプセル株式会社 | カプセル剤 |
JP2021024845A (ja) * | 2019-08-09 | 2021-02-22 | 日医工株式会社 | エルデカルシトール軟カプセル剤 |
JP2021024844A (ja) * | 2019-08-09 | 2021-02-22 | 日医工株式会社 | エルデカルシトール含有医薬組成物 |
KR20210024566A (ko) | 2018-06-27 | 2021-03-05 | 추가이 세이야쿠 가부시키가이샤 | 유지 중에 ed-71 및 그의 에폭시체를 포함하는 유분 분산체를 포함하는 의약 조성물 |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101785319B1 (ko) * | 2016-05-04 | 2017-10-17 | 대한뉴팜(주) | 안정성이 향상된 콜레칼시페롤 조성물 및 이의 제조방법 |
CN108420797B (zh) * | 2018-05-09 | 2022-05-03 | 南京海融制药有限公司 | 维生素d类似物制剂及其制备方法 |
CN111272902A (zh) * | 2020-03-16 | 2020-06-12 | 温州海鹤药业有限公司 | 一种艾地骨化醇血药浓度的检测方法 |
Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5312414A (en) | 1976-07-21 | 1978-02-03 | Chugai Pharmaceut Co Ltd | Production of preparation containing stable 1alpha-hydroxyvitamines d |
JPS63107929A (ja) * | 1986-06-05 | 1988-05-12 | Chugai Pharmaceut Co Ltd | 新規ビタミンd↓3誘導体を有効成分とする医薬 |
JPH02215765A (ja) * | 1989-02-15 | 1990-08-28 | Hoxan Corp | 22,23―セコ―1,7,8―トリヒドロキシビタミンdあるいはその誘導体とその製造方法 |
JPH054925A (ja) * | 1991-06-27 | 1993-01-14 | Teikoku Chem Ind Corp Ltd | アルフアカルシドール軟カプセル製剤 |
JPH0641060A (ja) * | 1992-02-27 | 1994-02-15 | Duphar Internatl Res Bv | 9ベータ,10アルフア−5,7−ジエンステロイド類の製造方法 |
JPH0687750A (ja) * | 1992-09-08 | 1994-03-29 | Taiyo Yakuhin Kogyo Kk | 医薬組成物 |
JPH1072432A (ja) * | 1996-07-01 | 1998-03-17 | Chugai Pharmaceut Co Ltd | ビタミンd誘導体結晶およびその製造方法 |
WO2001090061A1 (fr) * | 2000-05-23 | 2001-11-29 | Chugai Seiyaku Kabushiki Kaisha | Derives de 5, 6-trans-2-alkylevitamine d |
JP2002505668A (ja) * | 1997-05-16 | 2002-02-19 | ウィメン アンド インファンツ ホスピタル | 環状エーテルビタミンD3化合物、1α(OH)3−エピ−ビタミンD3化合物及びそれらの使用法 |
US6448421B1 (en) | 1996-07-01 | 2002-09-10 | Chugai Seiyaku Kabushiki Kaisha | Crystals of vitamin D derivatives and process for the preparation thereof |
WO2003047595A1 (en) | 2001-12-03 | 2003-06-12 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin d compounds |
US20030170324A1 (en) | 2002-01-15 | 2003-09-11 | Jean-Claude Tritsch | 25-Hydroxy Vitamin D3 compositions |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4666634A (en) * | 1984-12-05 | 1987-05-19 | Chugai Seiyaku Kabushiki Kaisha | vitamin D3 derivatives having a substituent at 2-position |
JPS63267706A (ja) * | 1987-04-22 | 1988-11-04 | Dainippon Jiyochiyuugiku Kk | ベンジルアルコ−ルエステルを含有する燻焼用及び加熱蒸散用殺虫剤ならびにその製造法 |
WO1994020143A1 (en) * | 1993-03-03 | 1994-09-15 | Fujisawa Pharmaceutical Co., Ltd. | Optical isomerization inhibitor |
EA003741B1 (ru) * | 1998-06-01 | 2003-08-28 | Энтони Дж. Вербискар | Местное трансдермальное лечение |
US6267985B1 (en) * | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
TW561047B (en) * | 1999-08-31 | 2003-11-11 | Chugai Pharmaceutical Co Ltd | Soft capsule formulations |
US6660306B2 (en) * | 2000-10-12 | 2003-12-09 | Mickey L. Peshoff | Wound healing compound |
US7094431B2 (en) * | 2000-10-12 | 2006-08-22 | Mickey L. Peshoff | Method of healing skin wounds in mammals and a composition therefor |
US8486374B2 (en) * | 2003-08-04 | 2013-07-16 | Foamix Ltd. | Hydrophilic, non-aqueous pharmaceutical carriers and compositions and uses |
-
2005
- 2005-02-07 CN CN2009102228115A patent/CN101721708B/zh not_active Ceased
- 2005-02-07 CN CN2005800098776A patent/CN1938034B/zh not_active Ceased
- 2005-02-07 JP JP2005517763A patent/JP4921794B2/ja active Active
- 2005-02-07 US US10/588,609 patent/US20070129340A1/en not_active Abandoned
- 2005-02-07 KR KR1020067017923A patent/KR101166394B1/ko active IP Right Grant
- 2005-02-07 ES ES05709801.4T patent/ES2638836T3/es active Active
- 2005-02-07 WO PCT/JP2005/001749 patent/WO2005074943A1/ja active Application Filing
- 2005-02-07 EP EP05709801.4A patent/EP1714656B8/en active Active
-
2007
- 2007-08-27 HK HK07109267.0A patent/HK1101139A1/xx unknown
-
2010
- 2010-10-25 HK HK10110017.6A patent/HK1144179A1/xx not_active IP Right Cessation
-
2011
- 2011-11-24 JP JP2011256586A patent/JP5529104B2/ja active Active
Patent Citations (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5312414A (en) | 1976-07-21 | 1978-02-03 | Chugai Pharmaceut Co Ltd | Production of preparation containing stable 1alpha-hydroxyvitamines d |
JPS63107929A (ja) * | 1986-06-05 | 1988-05-12 | Chugai Pharmaceut Co Ltd | 新規ビタミンd↓3誘導体を有効成分とする医薬 |
JPH02215765A (ja) * | 1989-02-15 | 1990-08-28 | Hoxan Corp | 22,23―セコ―1,7,8―トリヒドロキシビタミンdあるいはその誘導体とその製造方法 |
JPH054925A (ja) * | 1991-06-27 | 1993-01-14 | Teikoku Chem Ind Corp Ltd | アルフアカルシドール軟カプセル製剤 |
JPH0641060A (ja) * | 1992-02-27 | 1994-02-15 | Duphar Internatl Res Bv | 9ベータ,10アルフア−5,7−ジエンステロイド類の製造方法 |
JPH0687750A (ja) * | 1992-09-08 | 1994-03-29 | Taiyo Yakuhin Kogyo Kk | 医薬組成物 |
JPH1072432A (ja) * | 1996-07-01 | 1998-03-17 | Chugai Pharmaceut Co Ltd | ビタミンd誘導体結晶およびその製造方法 |
US6448421B1 (en) | 1996-07-01 | 2002-09-10 | Chugai Seiyaku Kabushiki Kaisha | Crystals of vitamin D derivatives and process for the preparation thereof |
JP2002505668A (ja) * | 1997-05-16 | 2002-02-19 | ウィメン アンド インファンツ ホスピタル | 環状エーテルビタミンD3化合物、1α(OH)3−エピ−ビタミンD3化合物及びそれらの使用法 |
WO2001090061A1 (fr) * | 2000-05-23 | 2001-11-29 | Chugai Seiyaku Kabushiki Kaisha | Derives de 5, 6-trans-2-alkylevitamine d |
WO2003047595A1 (en) | 2001-12-03 | 2003-06-12 | Novacea, Inc. | Pharmaceutical compositions comprising active vitamin d compounds |
US20030170324A1 (en) | 2002-01-15 | 2003-09-11 | Jean-Claude Tritsch | 25-Hydroxy Vitamin D3 compositions |
Cited By (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2013139469A (ja) * | 2006-01-24 | 2013-07-18 | R Tec Ueno:Kk | 二環式化合物を含む医薬組成物およびその二環式化合物の安定化方法 |
US8669284B2 (en) | 2006-01-24 | 2014-03-11 | Sucampo Ag | Pharmaceutical composition comprising a bi-cyclic compound and method for stabilizing the bi-cyclic compound |
JP2009524578A (ja) * | 2006-01-24 | 2009-07-02 | 株式会社アールテック・ウエノ | 二環式化合物を含む医薬組成物およびその二環式化合物の安定化方法 |
JP2018528985A (ja) * | 2015-09-18 | 2018-10-04 | プラティ、ドナドゥッチ エー シア リミターダ | カンナビノイドを含む経口医薬組成物、その調製及び使用のための方法 |
JPWO2018124260A1 (ja) * | 2016-12-28 | 2019-10-31 | 中外製薬株式会社 | Ed−71の固体分散体および油分分散体を含む医薬組成物 |
CN110121348A (zh) * | 2016-12-28 | 2019-08-13 | 中外制药株式会社 | 包含ed-71的固体分散体及油分散体的药物组合物 |
KR20190101981A (ko) | 2016-12-28 | 2019-09-02 | 추가이 세이야쿠 가부시키가이샤 | Ed-71의 고체 분산체 및 유분 분산체를 포함하는 의약 조성물 |
WO2018124260A1 (ja) * | 2016-12-28 | 2018-07-05 | 中外製薬株式会社 | Ed-71の固体分散体および油分分散体を含む医薬組成物 |
JP2021155437A (ja) * | 2016-12-28 | 2021-10-07 | 中外製薬株式会社 | Ed−71の固体分散体および油分分散体を含む医薬組成物 |
KR20220025177A (ko) | 2016-12-28 | 2022-03-03 | 추가이 세이야쿠 가부시키가이샤 | Ed-71의 고체 분산체 및 유분 분산체를 포함하는 의약 조성물 |
JP7196239B2 (ja) | 2016-12-28 | 2022-12-26 | 中外製薬株式会社 | Ed-71の固体分散体および油分分散体を含む医薬組成物 |
JP2019014676A (ja) * | 2017-07-06 | 2019-01-31 | 東海カプセル株式会社 | カプセル剤 |
KR20210024566A (ko) | 2018-06-27 | 2021-03-05 | 추가이 세이야쿠 가부시키가이샤 | 유지 중에 ed-71 및 그의 에폭시체를 포함하는 유분 분산체를 포함하는 의약 조성물 |
JP7291138B2 (ja) | 2018-06-27 | 2023-06-14 | 中外製薬株式会社 | 油脂中にed-71およびそのエポキシ体を含む油分分散体を含む医薬組成物 |
JP2021024845A (ja) * | 2019-08-09 | 2021-02-22 | 日医工株式会社 | エルデカルシトール軟カプセル剤 |
JP2021024844A (ja) * | 2019-08-09 | 2021-02-22 | 日医工株式会社 | エルデカルシトール含有医薬組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN1938034B (zh) | 2010-12-08 |
US20070129340A1 (en) | 2007-06-07 |
KR101166394B1 (ko) | 2012-07-23 |
EP1714656A1 (en) | 2006-10-25 |
HK1144179A1 (en) | 2011-02-02 |
EP1714656B8 (en) | 2017-09-20 |
JPWO2005074943A1 (ja) | 2007-10-11 |
KR20070003904A (ko) | 2007-01-05 |
CN101721708A (zh) | 2010-06-09 |
EP1714656A4 (en) | 2012-10-31 |
CN101721708B (zh) | 2013-09-04 |
JP2012072169A (ja) | 2012-04-12 |
HK1101139A1 (en) | 2007-10-12 |
ES2638836T8 (es) | 2017-11-28 |
JP5529104B2 (ja) | 2014-06-25 |
JP4921794B2 (ja) | 2012-04-25 |
CN1938034A (zh) | 2007-03-28 |
EP1714656B1 (en) | 2017-08-16 |
ES2638836T3 (es) | 2017-10-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5529104B2 (ja) | Ed−71製剤 | |
CA2575587A1 (en) | Carrier for enteral administration | |
EP3288550B1 (en) | Structurally enhanced fatty acids containing sulphur for their use in treating non-alcoholic steatohepatitis | |
CN109562186A (zh) | 与炎症的专门促消退介质的盐有关的组合物和方法 | |
CA3162353A1 (en) | Oral cannabinoid formulations | |
CA3149652A1 (en) | Oral formulations of cannabis extracts and methods of making same | |
AU2015308614A1 (en) | Pharmaceutical composition and methods | |
WO2021163023A1 (en) | Stable formulations of dronabinol | |
US20090143484A1 (en) | Use of garlic oil to increase bioavailability of coenzyme q-10 | |
US20040110827A1 (en) | High enantiomeric purity dexanabinol for pharmaceutical compositions | |
KR101821440B1 (ko) | 비타민 d의 14-에피-유사체의 새로운 제제 | |
CN105601611A (zh) | 一种盐酸洛氟普啶多晶型物及其制备方法 | |
US8030358B2 (en) | Methods and pharmaceutical compositions for decorporation of radioactive compounds | |
JPS6346728B2 (ja) | ||
CN109394724A (zh) | 一种丁基苯酞液体硬胶囊制剂及其制备方法 | |
JP7406581B2 (ja) | 油脂中にed-71およびそのエポキシ体を含む油分分散体を含む医薬組成物 | |
CA2602464A1 (en) | Methods of treating osteoporosis and secondary hyperparathyroidism using 20-methyl, gemini vitamin d3 compounds | |
KR102708351B1 (ko) | 유지 중에 ed-71 및 그의 에폭시체를 포함하는 유분 분산체를 포함하는 의약 조성물 | |
EP4065592B1 (en) | Cocrystals of steroid and secosteroid compounds and compositions comprising them | |
SI26056A (sl) | Samonanoemulgirni koncentrat kanabinoidnoionskega kompleksa in metoda za njegovo pripravo | |
TW201836598A (zh) | 口服甲狀腺治療劑 | |
IE970758A1 (en) | Compounds | |
EP2890369A1 (en) | Pharmaceutical compositions comprising an active agent |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005517763 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007129340 Country of ref document: US Ref document number: 10588609 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2005709801 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005709801 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067017923 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200580009877.6 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2005709801 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067017923 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 10588609 Country of ref document: US |